# reload+after+2024-01-21 05:44:21.381601
address1§1633 Broadway
address2§22nd Floor Suite C
city§New York
state§NY
zip§10019
country§United States
phone§212 489 2100
fax§212 489 2102
website§https://www.delcath.com
industry§Medical Devices
sector§Healthcare
longBusinessSummary§Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
fullTimeEmployees§52
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Gerard J. Michel MBA, MS', 'age': 60, 'title': 'CEO & Director', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 671601, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. John  Purpura M.S.', 'age': 62, 'title': 'Chief Operating Officer', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 485921, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Johnny  John M.D.', 'age': 59, 'title': 'Senior Vice President Clinical Development & Medical Affairs', 'yearBorn': 1964, 'fiscalYear': 2022, 'totalPay': 472163, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Sandra  Pennell', 'age': 44, 'title': 'Senior VP of Finance and Principal Financial & Accounting Officer', 'yearBorn': 1979, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. David  Hoffman', 'title': 'General Counsel, Corporate Secretary & Chief Compliance Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Vojislav  Vukovic M.D., Ph.D.', 'age': 56, 'title': 'Chief Medical Officer', 'yearBorn': 1967, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.527
priceToSalesTrailing12Months§41.85195
currency§USD
dateShortInterest§1702598400
forwardEps§-1.37
pegRatio§-0.09
exchange§NCM
quoteType§EQUITY
shortName§Delcath Systems, Inc.
longName§Delcath Systems, Inc.
firstTradeDateEpochUtc§1525354200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§e634292b-7b25-3cd1-9b6a-45d8a0075f17
gmtOffSetMilliseconds§-18000000
targetHighPrice§22.0
targetLowPrice§13.0
targetMeanPrice§18.0
targetMedianPrice§18.0
recommendationMean§1.8
recommendationKey§buy
numberOfAnalystOpinions§5
quickRatio§2.91
grossMargins§0.67621005
ebitdaMargins§0.0
trailingPegRatio§None
